Hematology
Older Age Associated With Better Post-Transplant Survival in Newly Diagnosed AML
Older age linked to better post-transplant survival in AML patients treated with venetoclax and HMA, ASCO 2026 ...
JULY 21, 2026
Distinct Mutation Patterns in Black Patients Challenge Current AML Risk Stratification
Acute myeloid leukemia racial disparities persist as Black patients show distinct genomic patterns, challenging ...
JULY 20, 2026
Adult AML Survivors Face Heightened Risk for Additional Cancers
Adult acute myeloid leukemia survivors face higher risk of second cancers, underscoring need for long-term, ...
JULY 19, 2026
Emerging Therapies For Blood Cancers
Blood cancers 2025–2026: new AML, MCL, MM, and lymphoma therapies, including menin inhibitors and updated ...
JULY 3, 2026
A Synergy of CAR-T Hematotoxicity Scoring Tools
CAR-T therapy toxicity prediction: Study finds CAR-HEMATOTOX and KyoTox show similar accuracy but excel in ...
MAY 30, 2026
IV Iron During Acute Infection Linked to Lower Mortality, Real-World Analysis Finds
IV iron treatment during infection improves survival in hospitalized adults with iron deficiency anemia, ...
MAY 19, 2026
Pediatric Iron Deficiency: New Ferritin Thresholds, and a Wider Role for Pharmacy
Pediatric iron deficiency is being redefined, including new treatment guidelines that advocate for moving ferritin ...
MAY 19, 2026
KDIGO Updates Anemia in CKD Guideline After 14 Years
KDIGO Anemia 2026 guideline update redefines iron deficiency in chronic kidney disease and supports proactive IV ...
MAY 11, 2026
HOPA 2026: Emerging Off-Tumor Toxicities in CAR-T
Dr. Rebecca Gonzales discusses the incidence and mechanisms of novel toxicities due to off-tumor binding that may ...
APRIL 21, 2026
FDA Grants Accelerated Approval to Lynozyfic for Relapsed or Refractory Multiple Myeloma
The FDA granted accelerated approval to Lynozyfic, a BCMA-directed CD3 T-cell engager for adults with relapsed or ...
JULY 8, 2025
FDA Approves Qfitlia for Hemophilia A or B
The FDA approved Qfitlia for adults and children 12 years of age and older with hemophilia A or B, with or without ...
APRIL 7, 2025
Daratumumab Delays Transition From Smoldering to Active Multiple Myeloma
In a phase 3 trial, the anti-38 monoclonal antibody Darzalex substantially delayed or prevented transformation of ...
FEBRUARY 20, 2025
